Zanzalintinib (XL092)

Name: Zanzalintinib (XL092) in Metastatic colorectal cancer: Access and distribution
Published: 2026-09-14T15:39:06-04:00

Metastatic colorectal cancer

Manufacturer: Exelixis
Regulatory submission: NDA submitted December 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Access and distribution

1 evidence topic · 1 source

Access to investigational treatment

“Early access is only available in limited circumstances for certain types of patients for which no other treatment options exist.” (opens the source at this quote in a new tab)

Commercial distribution arrangements and zanzalintinib-specific patient assistance

No evidence found.